Can a gel tame psoriasis? new antibody fragment put to the test

NCT ID NCT06380907

Terminated Disease control Sponsor: Zai Lab (Hong Kong), Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether a topical gel containing ZL-1102, an antibody fragment that blocks IL-17A, can safely and effectively reduce the severity of chronic plaque psoriasis. The study enrolls adults with psoriasis for at least six months and compares different doses of the gel against a placebo over 16 weeks. The main goal is to see if at least a 75% improvement in skin symptoms is achieved, with secondary measures tracking overall skin clearance and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZL-1102 topical gel, a human antibody fragment targeting IL-17A
What this could lead to: If successful, this could offer a new topical, non-steroidal option for managing chronic plaque psoriasis, potentially reducing skin plaques with fewer systemic side effects.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not hold up in larger studies. The gel's effectiveness and safety are still unproven, and it may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Locations

Zai Lab Site 5002

Melbourne E., Victoria, 3002, Australia
Zai Lab Site 5013

Phillip, Australian Capital Territory, 2606, Australia
Zai Lab Site 5014

Carlton, Victoria, 3053, Australia
Zai Lab Site 5015

Melbourne, Victoria, 3124, Australia
Zai Lab Site 5016

Kotara, New South Wales, 2289, Australia
Zai Lab Site 5017

Woolloongabba, Queensland, 4102, Australia
Zai Lab Site 5018

Parkville, Victoria, 3050, Australia
Zai Lab Site 5019

Coorparoo, Queensland, 4151, Australia
Zai Lab Site 5020

Birtinya, Queensland, 4375, Australia
Zai Lab Site 5021

Kogarah, New South Wales, 2217, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.